iCAD (NASDAQ:ICAD) Downgraded to Sell Rating by StockNews.com

StockNews.com cut shares of iCAD (NASDAQ:ICAD) from a hold rating to a sell rating in a research note released on Wednesday morning.

iCAD Stock Performance

NASDAQ ICAD opened at $3.53 on Wednesday. iCAD has a 52 week low of $1.18 and a 52 week high of $3.78. The stock’s 50 day moving average price is $2.27 and its two-hundred day moving average price is $1.85.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ICAD. Perritt Capital Management Inc boosted its stake in shares of iCAD by 1.9% during the 4th quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company’s stock worth $346,000 after buying an additional 3,600 shares during the last quarter. waypoint wealth counsel boosted its position in iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after purchasing an additional 4,400 shares during the last quarter. Wells Fargo & Company MN grew its stake in iCAD by 51.3% in the fourth quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after purchasing an additional 13,402 shares in the last quarter. Thompson Davis & CO. Inc. acquired a new position in shares of iCAD during the 4th quarter worth approximately $31,000. Finally, Geode Capital Management LLC raised its stake in shares of iCAD by 6.6% during the 4th quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company’s stock worth $506,000 after purchasing an additional 17,059 shares in the last quarter. Institutional investors own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.